Hohenheim, Univ., Diss., 2007.

Thesis (M. Sc.)--Memorial University of Newfoundland, Faculty of Medicine, 1998. / Typescript. Bibliography: leaves 68-81.

Techn. Universiẗat, Diss., 2005--Darmstadt.

The serotonergic system is involved in a broad range of functions in both vertebrates and invertebrates and is highly conserved across taxa. Serotonin is an important monoamine acting in the brains of humans and animals, and has large and varying influences on many aspects of an individual’s life. For example, in humans, serotonin modulates feelings of happiness and in fruit flies, higher levels of serotonin increase aggression. In humans, an abnormal serotonergic system can result in health issues, such as depression and obsessive compulsive disorders, for which medications have been developed, including selective serotonin reuptake inhibitors (SSRI). Because the serotonin system has a large influence on human health, understanding how it functions is of great interest to researchers. Using comparative studies to explore differences in the serotonin system across taxa can provide insight into the mechanistic details of the system. To investigate if the serotonin system is comparable between vertebrates and invertebrates, a literature study with particular focus on receptors and proteins involved was performed. In addition, this report takes part in an experimental study investigating the effect of the SSRI fluoxetine in Mediterranean field crickets.  Fluoxetine reduced exploration propensity of crickets, which was reversed, compared to what was anticipated and compared to effects seen in vertebrates. The literature review suggests that serotonin receptors are quite similar, but that proteins differ more when comparing vertebrates and invertebrates. This offers a likely explanation as to why results of studies on these different groups of animals may differ.

Fluoxetine, a selective serotonin re-uptake inhibitor (SSRI) and the active ingredient in Prozac®, is found in the environment and disrupts feeding and metabolism in exposed fish. The objective of this research was to investigate the mechanisms involved in the feeding and metabolism disruption in the model goldfish (Carassius auratus). Two short-term waterborne fluoxetine exposures (7- and 14-days) were performed using two environmentally relevant doses of fluoxetine (0.5 and 1 μg/L) and metabolic effects at the level of the brain, liver, serum and bile in goldfish were investigated. Abundances of mRNA transcripts coding for six feeding neuropeptides were examined to determine which may be involved in the initial neural changes associated with decreased appetite in goldfish. The 7-day fluoxetine exposure at 1 μg/L caused corticotropin-releasing factor (CRF) mRNA levels to increase by 2-fold in female hypothalamus and telencephalon, indicating that CRF may be one of the first of the feeding neuropeptides to be altered. Six hepatic miRNAs were also evaluated in the goldfish liver that were previously associated with fluoxetine exposure in zebrafish (Danio rerio). Following the 7-day exposure at 1 μg/L, miR-22b, miR-140, miR-210, miR-301a and miR-457b levels increased in the female goldfish liver by 4-6 fold. The 14-day fluoxetine exposure at 1 μg/L caused 2-fold increases in miR-210, miR-301a, miR-457b and let-7d in male goldfish liver. These miRNAs were associated with the down-regulation of anabolic metabolic pathways in zebrafish, indicating a conservation of miRNA and fluoxetine effect between fish species. Serum and bile metabolite profiles of fluoxetine exposed goldfish were evaluated using ultra performance liquid chromatography coupled to quadrupole time of flight mass spectrometry. Following the 14-day exposure at 1 μg/L, the bile metabolite profiles of male goldfish were significantly different from controls as detected by cluster analysis and fluoxetine was tentatively identified in the serum. No other discriminant metabolites were identified as of yet. The data presented suggest that fluoxetine causes metabolic disruption in goldfish at multiple organ levels. Because of the widespread detection of fluoxetine and other emerging SSRIs in the aquatic environment, future research is required to firmly establish this pharmaceutical class as a metabolic and endocrine disrupting chemical.

his study compared auditory behavioral and physiological measures among three subject groups: 1) Normal control subjects, 2) subjects who were on a prescribed SSRI for depression, and 3) subjects who were prescribed an SSRI for depression, but were not medicated at the time of testing. Test measures included: Standard audiological tests (audiometry and tympanometry), electrophysiological procedures for analysis of auditory- evoked brainstem and late responses, and standardized behavioral speech tests (SCAN-A, SSI, and the low predictability sentence list of the R-SPIN). Analysis of results indicated a statistically significant increase of group mean amplitude of the ABR peak V, from 15dBnSL to 55dBnSL, in the non-medicated group compared to controls. Also, the non-medicated group scored significantly less favorably than controls on the most challenging listening condition (-20 MCR) of the SSI, in the left ear. Although other test measures indicated consistent differences between these two groups, they were not, however, significant.

The purpose of this study was to investigate the relationship between selective serotonin reuptake inhibitor (SSRI) medication on auditory skills in clinically depressed subjects. Experimental subjects prescribed an SSRI were tested in a medicated and an unmedicated condition, and the test results were compared. Furthermore, the experimental group was compared with a control group consisting of normal subjects. Test measures included pure tone audiometry, tympanometry, acoustic reflex thresholds, and auditory electrophysiologic measures such as auditory brainstem and auditory late responses. An assessment scale for depression (Beck Depression Inventory-II) was also used. Results indicated statistically significant differences for the BDI-II between the control and experimental groups for both conditions. Electrophysiologic measures indicated a significantly shorter latency for auditory late potential P1 at 55 dBnSL, and a significantly larger amplitude at 45 dBnSL for the N1/P2 component for the unmedicated group. Although the other measures showed trends, they did not reach significance.

No description available.

Indiana University-Purdue University Indianapolis (IUPUI) / Serotonin (5-hydroxytryptamine, 5-HT) is a monoamine neurotransmitter that is synthesized from the amino acid L-tryptophan and is reported to localize in mitochondria of embryonic stem cells. Even before its role as a neurotransmitter in mature brain was discovered, 5-HT has been shown to play an important role in regulating brain development. However, there is a lack of knowledge about the downstream target genes regulated by serotonin in embryonic stem (ES) cells. Towards this end, our study helps in understanding transcriptional regulatory mechanisms of 5-HT responsive genes in ES cells. By combining the gene expression data with motif prediction algorithms, literature validation and comparison with public domain data, gene targets specific to endogenous or exogenous 5-HT in ES cells were identified. By performing one-way ANOVA, and volcano plots using GeneSpring software, we identified 44 5-HT induced and 29 5-HT suppressed genes, likely to be transcriptionally regulated by 4 & 2 TFs respectively. Motif enrichment analysis on these target genes using MotifScanner revealed that the transcription factor TFAP2A plays a key role in regulating the expression of 5-HT responsive genes. Furthermore, by comparing our dataset with published expression profiles of ES cells, we observed a number of 5-HT responsive target genes showing enrichment in ES cells. Genes such as Nanog, Slc38a5, Hoxb1 and Eif2s1 from this analysis have been observed to be components of ‘stemness’ phenotypes reported in literature. Functional annotation of the 5-HT responsive genes identified gene ontologies such as regulation of translation in response to stress and energy derivation by oxidation, suggesting a regulatory role for 5-HT in mitochondrial functions of ES cells. Additionally, enrichment of other biological process terms such as development of various parts of nervous system, cell adhesion, and apoptosis suggests that 5-HT target genes may play an important role in ES cell differentiation. Our study implemented a new combinatorial approach for identifying gene regulatory mechanisms involved in 5-HT responsive genes and proposed potential mediatory role for serotonin in ES cell differentiation and growth. Thus, this study provides potential 5-HT target genes in ES cells for biological validation.

Depression is a common neuropsychiatric illness with a lifetime prevalence of 17% in the United States. The disease can severely impact the daily living and quality of life in patients. The monoamine hypothesis of depression implicates the neurotransmitter serotonin as mediating the pathophysiology. Selective serotonin reuptake inhibitors (SSRIs), a popular and efficacious class of antidepressants, increase serotonin concentrations in the brain. However, full clinical benefit may not be obtained for four to six weeks. This period of waiting for SSRIs to work becomes quite daunting for patients. Research has focused on delineating the control mechanisms surrounding the dorsal raphé nucleus (DRN), the serotonergic control center located in the midbrain. Much evidence points to changes in several receptor systems as the underlying cause of the delay. One particular serotonin receptor, 5-HT 1A , has been established to play a role in affecting the time course of clinical effect. We have targeted another receptor as a possible contributor to the delay: the stimulatory 5-HT 2A heteroreceptors located on GABAergic interneurons of the DRN. The 5-HT 2A receptors of the GABAergic interneurons receive stimulatory input from serotonergic collaterals branching off the DRN serotonergic neurons. The resultant stimulation causes GABA release and inhibition of the serotonergic neurons via GABA A receptors of the DRN, completing a feedback loop. We hypothesize that the 5-HT 2A receptors desensitize under constant stimulation, as in the case with SSRI administration, and as a result contribute to the time delay in the onset of action of SSRIs. Using the microdialysis technique, various receptor agonists and antagonists were administered to examine receptor changes and its influence on serotonin release in male Wistar rats. Our results demonstrate that GABA A receptors exert a large inhibitory influence on serotonergic neurotransmission. Local GABA release results from 5-HT 2A receptor stimulation. Furthermore, serotonin appears to trend back towards basal levels, suggesting a possible desensitization process occurring under constant agonism of 5-HT 2A receptors. The development of our pharmacodynamic model quantitatively shows a slow desensitization process, which may also contribute to the time delay observed with the onset of action of SSRIs.